Event Details
Agenda
Event Details
Meeting Purpose
Patients with Chronic Kidney Diseases (CKDs) frequently experience disturbances of mineral metabolism resulting in systemic effects on the blood, bone, and vasculature. Iron and phosphate are important to maintain these systems; however, the biological signals controlling their regulation are only partly understood. Fibroblast Growth Factor 23 (FGF-23), a bone-derived hormone, regulates systemic phosphate homeostasis. Its discovery also has revealed novel interactions between phosphate and iron homeostasis. The NIDDK extramural research community offers a wealth of existing resources, infrastructure, and expertise that could accelerate the progress in this developing research area. Interdisciplinary approaches to understanding the physiologic and molecular regulators of phosphate and iron among patients with CKDs may identify novel diagnostic tools, new interventions, and improve clinical outcomes.
Organizing Committee
External Organizers
Tomas Ganz, M.D., Ph.D.; University of California, Los Angeles
Alan Go, M.D.; Kaiser Permanente Division of Research
Sharon Moe, M.D.; Indiana University
Orson Moe, M.D.; University of Texas Southwestern Medical Center
Isidro Salusky, M.D.; University of California, Los Angeles
Myles Wolf, M.D.; Duke University
NIH Organizers
Kevin Abbott, M.D., M.P.H.; NIDDK/KUH
Bonnie Burgess-Beusse, Ph.D.; NIDDK/DDN
Faye Chen, Ph.D.; NIAMS/DMD
Michael Flessner, M.D., Ph.D.; NIDDK/KUH
Daniel Gossett, Ph.D.; NIDDK/KUH
Chris Ketchum, Ph.D.; NIDDK/KUH
Paul Kimmel, M.D.; NIDDK/KUH
John Kusek, Ph.D.; NIDDK/KUH
Saul Malozowski, M.D., Ph.D., M.B.A.; NIDDK/DEM
Marva Moxey-Mims, M.D.; NIDDK/KUH
Cindy Roy, Ph.D.; NIDDK/KUH
Krystyna Rys-Sikora, Ph.D.; NIDDK/KUH
Jason Wan, Ph.D.; NIDCR/IBIDB
John Williams, Ph.D.; NIA/DAB
Registration Deadline
March 26, 2017
Agenda
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) acknowledges the support of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in the development of this joint program.
March 27, 2017
- 7:30 a.m.
- Registration and Poster Setup
- 8:00 a.m.
- Welcome
Griffin P. Rodgers, M.D., MACP, Director, NIDDK
Robert Star, M.D., Director, Division of Kidney, Urologic and Hematologic Diseases, NIDDK
- 8:20 a.m.
- Meeting Purpose and Logistics
Cindy Roy, Ph.D., NIDDK
- 8:40 a.m.
- Introduction, Barriers, Opportunities
Myles Wolf, M.D., Duke University
Session 1: What Is Fibroblast Growth Factor (FGF)-23? What Does It Do?
Moderator: Faye Chen, Ph.D., NIAMS
- 9:00 a.m.
- FGF-23 and the Regulation of Phosphate Homeostasis
Kenneth White, Ph.D., Indiana University-Purdue University Indianapolis
- The Current State of Structural Biology of FGF-23 Signaling
Moosa Mohammadi, Ph.D., New York University
- 10:00 a.m.
- Break
Session 2: Measuring FGF-23 in Patients and Populations
Moderator: Jason Wan, Ph.D., National Institute of Dental and Craniofacial Research
- 10:30 a.m.
- TBD
Orson Moe, M.D., The University of Texas Southwestern Medical Center
- TBD
Myles Wolf, M.D., Duke University
- 11:30 a.m.
- Lunch and Posters
Session 3: Impact of FGF-23 in Kidney Diseases 1
Moderator: Krystyna Rys-Sikora, Ph.D., NIDDK
- 12:30 p.m.
- The Effects of Iron and Erythropoietin on FGF-23 Production
Tomas Ganz, M.D., Ph.D., University of California, Los Angeles
- FGF-23: Cross-talk Between Inflammation and Iron Metabolism
Nicolae Valentin David, Ph.D., Northwestern University
- FGF-23 and Bone in Chronic Kidney Disease (CKD)
Isidro Salusky, M.D., University of California, Los Angeles
- 2:00 p.m.
- Break
Session 4: Impact of FGF-23 in Kidney Diseases 2
Moderator: Pothur Srinivas, Ph.D., M.P.H., National Heart, Lung, and Blood Institute
- 2:30 p.m.
- Direct Pathologic Actions of FGF-23 in CKD
Christian Faul, Ph.D., University of Miami
- FGF-23 and Cardiovascular Disease Risk in the Community: Insights from the Framingham Heart Study and an Overview of the Literature
Vasan Ramachandran, M.D., Framingham Heart Study/Boston University
- Impact of the FGF-23/α-Klotho/Phosphate Axis in Vascular Calcification
Cecilia Giachelli, Ph.D., University of Washington
- FGF-23 and Mortality in Critically Ill Patients
David Leaf, M.D., Brigham and Women’s Hospital
- 4:30 p.m.
- Discussion Session 1
Moderators: Myles Wolf, M.D., Duke University, and Chris Ketchum, Ph.D., NIDDK
March 28, 2017
- 7:30 a.m.
- Registration and Poster Setup
- 8:00 a.m.
- Introductions and Logistics
Session 5: Clinical Considerations
Moderator: Kevin Abbott, M.D., M.P.H., NIDDK
- 8:30 a.m.
- FGF-23 Assays: Strengths and Limitations
Harald Jüppner, M.D., Massachusetts General Hospital
- Potential Role of FGF-23 in Improving Risk Stratification of and Prognosis for Clinical Outcomes in CKD
Alan Go, M.D., Kaiser Permanente
- Cardiovascular Disease in CKD—Not So Straightforward!
Sharon Moe, M.D., Indiana University
- Dietary Considerations for Patients and Trial Participants
Orlando Gutierrez, M.D., The University of Alabama at Birmingham
- Entry Criteria, Efficacy Endpoints and Safety Considerations: A Regulatory Perspective
Aliza Thompson, M.D., U.S. Food and Drug Administration
Session 6: Industry Panel
Moderators: Daniel Gossett, Ph.D., and Paul Kimmel, M.D., NIDDK
- 11:00 a.m.
- Valerie Clerin, Ph.D., Pfizer, Inc.
Kerry Cooper, M.D., Amgen
Paul Korner, M.D., Ardelyx, Inc.
John F. Neylan, M.D., Keryx Biopharmaceuticals, Inc.
Amit Sharma, M.D., Akebia Therapeutics, Inc.
- 12:30 p.m.
- Lunch and Posters
- 1:30 p.m.
- Discussion Session 2
Moderators: Alan Go, M.D., Kaiser Permanente, and Paul Kimmel, M.D., NIDDK
Session 7: Therapeutics: Approaches to FGF-23
Moderator: Marva Moxey-Mims, M.D., NIDDK
- 2:30 p.m.
- KRN23, a Fully Human Monoclonal Antibody to FGF-23, Reverses Renal Phosphate Wasting and Improves Bone Disease in Children and Adults with X-linked Hypophosphatemia (XLH)
Anthony Portale, M.D., University of California, San Francisco
- FGF-23-related Endpoints for Consideration in Future Clinical Trials Relevant to Adult and Pediatric CKD Populations
Tamara Isakova, M.D., Northwestern University
- 3:30 p.m.
- Discussion Session 3
Moderators: Sharon Moe, M.D., Indiana University, and John Kusek, Ph.D., NIDDK
- 4:30 p.m.
- Summary and Future Directions
Robert Star, M.D., Director, Division of Kidney, Urologic and Hematologic Diseases, NIDDK
